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Abstract
Clinical strains of HCMV encode 20 putative ORFs within a region of the genome termed ULb9 that are postulated to encode
functions related to persistence or immune evasion. We have previously identified ULb9-encoded pUL138 as necessary, but
not sufficient, for HCMV latency in CD34
+ hematopoietic progenitor cells (HPCs) infected in vitro. pUL138 is encoded on
polycistronic transcripts that also encode 3 additional proteins, pUL133, pUL135, and pUL136, collectively comprising the
UL133-UL138 locus. This work represents the first characterization of these proteins and identifies a role for this locus in
infection. Similar to pUL138, pUL133, pUL135, and pUL136 are integral membrane proteins that partially co-localized with
pUL138 in the Golgi during productive infection in fibroblasts. As expected of ULb9 sequences, the UL133-UL138 locus was
dispensable for replication in cultured fibroblasts. In CD34
+ HPCs, this locus suppressed viral replication in HPCs, an activity
attributable to both pUL133 and pUL138. Strikingly, the UL133-UL138 locus was required for efficient replication in
endothelial cells. The association of this locus with three context-dependent phenotypes suggests an exciting role for the
UL133-UL138 locus in modulating the outcome of viral infection in different contexts of infection. Differential profiles of
protein expression from the UL133-UL138 locus correlated with the cell-type dependent phenotypes associated with this
locus. We extended our in vitro findings to analyze viral replication and dissemination in a NOD-scid IL2Rcc
null-humanized
mouse model. The UL133-UL138NULL virus exhibited an increased capacity for replication and/or dissemination following
stem cell mobilization relative to the wild-type virus, suggesting an important role in viral persistence and spread in the
host. As pUL133, pUL135, pUL136, and pUL138 are conserved in virus strains infecting higher order primates, but not lower
order mammals, the functions encoded likely represent host-specific viral adaptations.
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Introduction
Human cytomegalovirus (HCMV) is a member of the b-
herpesvirus subfamily that, like all herpesviruses, persists indefi-
nitely in infected individuals through a latent infection. HCMV
persistence is associated with an increased risk of age-related
pathologies including atherosclerosis [1,2], immune senescence
[3,4,5] and frailty [6,7,8] in otherwise healthy individuals.
Reactivation of HCMV from latency in individuals with
compromised T cell immunity, including transplant and AIDS
patients, is a significant cause of morbidity and mortality
[9,10,11,12]. Further, HCMV is the leading cause of infectious
disease-related birth defects [12,13,14]. The mechanisms control-
ling the outcome of infection, and in particular the latent infection,
in the diverse cell types infected by HCMV in the human host are
poorly understood. Understanding these mechanisms is essential to
ultimately controlling the overt viral pathologies in individuals
with weakened or insufficient T cell-mediated immunity as well as
non-overt pathologies associated with viral persistence.
Clinical isolates of HCMV uniformly contain a unique region of
the genome, termed ULb9, that encodes 20 predicted open reading
frames (ORFs) [15,16,17]. While the actual coding potential is
known for only a few ULb9 ORFs, these ORFs are considered
dispensable for viral replication in laboratory models such as
fibroblasts since laboratory-adapted strains of the virus lacking the
entire ULb9 region replicate with increased kinetics and to
increased viral yields relative to clinical strains. As such, it is
postulated that ULb9 ORFs function in latency, immune evasion,
virus dissemination in the host, or other aspects of pathogenesis.
We have previously identified sequences in the ULb9 region of the
HCMV genome encoding the UL138 protein (pUL138) that are
required for a latent infection in CD34
+ hematopoietic progenitor
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coding sequence (cds) results in a virus that replicates with
increased efficiency relative to the wild-type virus in HPCs in the
absence of a reactivation stimulus. While disruption of UL138
ablates the latent phenotype, a more robust loss of latency
phenotype results from the disruption of additional ULb9
sequences around and including the UL138 locus, indicating that
other viral sequences in addition to UL138 contribute to the
outcome of infection in HPCs. The mechanism by which pUL138
functions in viral latency is unknown; however, it has recently been
reported that the pUL138 enhances levels of tumor necrosis factor
receptor (TNFR) on the cell surface [20,21].
We have recently reported that UL138 is part of a larger 3.6-kb
polycistronic locus [22]. pUL138 is expressed from the 39 end of
three overlapping transcripts (3.6-, 2.7-, and 1.4-kb) by both
canonical and stress-inducible alternative mechanisms of transla-
tion initiation [19,22]. These transcripts encode three additional
putative ORFs, UL133, UL135, and UL136 upstream of UL138.
We detected proteins derived from these ORFs during transient
expression of UL138 cDNAs, as well as during HCMV infection
[22]. This locus may serve to coordinate the expression of
pUL133, pUL135, pUL136 and pUL138 for a common function
in dictating the outcome of infection in the cell.
The present study represents an initial characterization of the
unique HCMV genetic locus encoding UL133, UL135, UL136,
and UL138, the proteins expressed from this locus, and the role of
the locus in infection. We collectively refer to this locus as the
UL133-UL138 locus. pUL133, pUL135, and pUL136 are
previously uncharacterized proteins. Like pUL138, pUL133,
pUL135, and pUL136 were expressed early during productive
infection and ultimately localized to the Golgi apparatus. These
proteins were each associated with the Golgi as integral membrane
proteins with large C-terminal cytosolic domains. Despite
localization to the Golgi, pUL133, pUL135, pUL136, and
pUL138 were only partially co-localized. We hypothesized that
the UL133-UL138 locus functions in mediating context-dependent
outcomes of infection. As would be expected for ULb9 sequences,
the UL133-UL138 locus was dispensable for viral replication in
primary fibroblasts. We demonstrate that like UL138, the UL133-
UL138 locus or UL133 alone impeded replication in CD34
+
HPCs, consistent with a role for the encoded proteins in latency.
Surprisingly, the locus augmented replication in endothelial cells.
The disparate cell-type dependent phenotypes associated with the
UL133-UL138 locus correlated with differential profiles of
expression from the locus in endothelial and CD34
+ HPCs. While
all four proteins were expressed in fibroblasts, we fail to detect
pUL136 in endothelial cells and do not detect pUL135 or pUL136
in CD34
+ HPCs. Further, the UL133-UL138NULL virus exhibited
an increased capacity for replication and/or dissemination in a
NOD-scid IL2Rcc
null-humanized mouse model following stem cell
mobilization relative to the wild-type virus, further suggesting an
important role for the UL133-UL138 locus in latency and
reactivation. The role of individual proteins encoded by this locus
in infection and latency awaits further investigation. These
proteins likely represent virus adaptations to higher order primates
acquired through co-speciation as the protein sequences are
conserved in chimpanzee CMV (ChCMV) and to some extent in
rhesus CMV (RhCMV), but are not present in CMV strains
infecting lower vertebrates. Our work defines a novel locus that
underscores the complexity of the virus-host interactions govern-
ing HCMV replication.
Results
Kinetics of UL133-UL138 protein expression during
productive infection
We have previously demonstrated the coding potential of
UL133, UL135 and UL136 within the ULb9 region of the HCMV
genome [22]. pUL133, pUL135, and pUL136 are encoded by
three polycistronic transcripts of 3.6-kb, 2.7-kb and 1.4-kb,
respectively, which also encode pUL138, an established determi-
nant of HCMV latency [19,22]. The expression of the transcripts
is sensitive to inhibition of protein synthesis, but not to inhibition
of viral DNA synthesis, indicating early kinetics of expression [19].
In the present study, we have characterized the expression and
localization of these novel proteins as well as identified a role for
this novel locus in infection.
To aid in the analyses of pUL133, pUL135, pUL136, and
pUL138, we constructed a series of recombinant viruses in the
BAC clones of the FIX strain of CMV. We inserted the myc
epitope tag in-frame at the 39 terminus of each ORF (Figure 1A).
The resulting viruses are termed FIX-UL133myc, FIX-UL135myc,
FIX-UL136myc [22], and FIX-UL138myc [19]. The kinetics of
productive viral replication in primary human embryonic
fibroblasts (MRC5) infected with each of these viruses or the
parental strain, FIX-WT, were measured by TCID50 over a time
course. Despite variation in the eclipse phase, the recombinant
viruses containing epitope tags replicated with kinetics and to
yields reflecting that of the wild-type virus in MRC5 cells
(Figure 1B and S1). The differences between the viral yields are
not significant. The analogous recombinant viruses were also
made in the TB40E strain of HCMV. TB40E viruses also
replicated with wild-type kinetics similar to the FIX viruses.
To analyze the kinetics of pUL133, pUL135, pUL136, and
pUL138 expression, MRC5 cells were infected with FIX-
UL136myc (Figure 1C) or TB40E-UL136myc (Figure 1D) at a
multiplicity of infection (MOI) of 2. FIX-UL136myc was used in
these experiments to aid in the detection of pUL136 because this
protein is expressed at low levels in infected cells and we have not
been able to generate an adequate UL136-specific antibody.
Proteins were detected by immunoblotting with a monoclonal
antibody specific to the myc epitope tag to evaluate pUL136 or
Author Summary
Human cytomegalovirus is a ubiquitous herpesvirus that,
like all herpesviruses, establishes a life long relationship
with its host through a latent infection. The molecular
basis of viral latency is poorly understood, in part, because
viral determinants of latency and the corresponding virus-
host interactions are not well defined. We have identified a
polycistronic locus encoding the pUL138 latency determi-
nant, as well as three previously uncharacterized proteins,
pUL133, pUL135, and pUL136. We have characterized this
novel locus, the proteins it encodes and demonstrated the
role of the locus in modulating viral replication depending
on the context of infection. While this locus is dispensable
for productive replication in fibroblasts, it adversely
impacts virus replication in primary hematopoietic cells,
suggesting a role in establishing latency. Surprisingly, the
locus is required for efficient replication in primary human
endothelial cells. To our knowledge this is the first
demonstration of a viral locus that can have positive,
negative, or null effects on viral replication depending on
the context of infection. Our work defines exciting new
primate strain-specific determinants mediating viral repli-
cation and latency and exemplifies the complex nature of
virus-host interactions in cytomegalovirus infection.
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pUL138 [19,22]. pUL133 and pUL135 have an apparent
molecular mass of 39- and 43-kDa, respectively. Similar to
pUL138, pUL133 and pUL135 were expressed by 12 hours post
infection (hpi). pUL133 and pUL138 were expressed throughout
the time course of 120 hpi, while pUL135 expression tapered off
dramatically at 84 hpi. Multiple isoforms of pUL136 were detected
at 37-kDa, 27-kDa, and 20-kDa, termed pUL136-37K, pUL136-
27K, and pUL136-20K, respectively. An additional minor isoform
was detected at 24-kDa. The 27K and 20K isoforms of pUL136
are predominantly expressed by 12 hpi and persist throughout the
time course of infection. pUL136-37k exhibited slightly delayed
kinetics of expression and was detected robustly at 36 hpi. Further
studies are required to determine the origins of the pUL136
isoforms. Presumably, full-length pUL136 is derived from the 3.6-
and 2.7-kb transcripts encoding UL138. We previously detected at
least one smaller pUL136 isoform expressed from the 1.4-kb
UL138 transcript [22]. The relative ratios of the pUL136 isoforms
differ in the TB40E infection relative to the FIX expression. This
difference was consistently observed in multiple experiments;
however, the reason for this difference is not known. The dynamic
expression of pUL133, pUL135, and pUL136 from the UL138
transcripts and their expression patterns are intriguing and may
have important implications for their function during infection.
pUL133, pUL135, and pUL136 localize to the Golgi
apparatus
We previously determined that pUL138 localized to the Golgi
apparatus during infection or transient expression [19]. To
determine the subcellular localization of pUL133, pUL135, and
pUL136, we infected MRC5 fibroblasts with FIX-UL133myc, FIX-
UL135myc, or FIX-UL136myc at an MOI of 2 and analyzed the
subcellular distribution of each protein at 24 and 48 hpi by indirect
immunofluorescence using a monoclonal antibody specific to the
myc epitope tag. Cells were co-stained with an antibody against
the Golgi marker GM130 and with DAPI to identify the nucleus.
Cells infected with FIX-UL138myc were used as a reference.
Figure 1. Construction and characterization of recombinant viruses expressing myc tagged ORFs. (A) Schematic of the ULb9 locus
encoding UL133-UL138. The UL133myc, UL135myc, UL136myc, and UL138myc recombinant viruses generated in the FIX strain expressing individual ORFs
with an in frame C-terminal myc epitope tag (black arrow heads) are shown. (B) Multistep growth curves for FIX recombinant viruses. Fibroblasts were
infected at 0.2 MOI and virus titers measured by TCID50 over the time course indicated. (C–D) Kinetics of protein expression during productive
infection. Fibroblasts were mock infected or infected with (C) FIX-UL136myc virus or (D) TB40E-UL136myc virus at an MOI of 1. Cells were harvested at
12 hr intervals and cell lysates prepared from equal numbers of cells were analyzed by immunoblotting using either rabbit anti-myc to detect pUL136
or rabbit polyclonal antibodies directed against each HCMV protein. a-tubulin serves as a loading control.
doi:10.1371/journal.ppat.1002444.g001
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Golgi similarly to pUL138myc (Figure 2). pUL136myc resembled
pUL138 in that pUL136myc was Golgi associated at both 24 and
48 hpi. FIX-or TB40E-UL136myc express myc-tagged versions of
all pUL136 isoforms (Figure 1C and 1D); however, these forms
cannot be differentiated in these experiments. pUL133myc and
pUL135myc exhibited more diffused cellular staining at 24 hpi with
predominant localization to the Golgi by 48 hpi.
pUL133, pUL135, and pUL136 are integral membrane
proteins
Similar to pUL138, pUL133, pUL135, and the full-length
pUL136 isoform(s) are predicted to have amino terminal
transmembrane (TM) domains (Figure 3A). The TM domains
predicted for pUL135 and pUL136 span the membrane once,
whereas pUL133 has two predicted membrane spanning domains.
We investigated the membrane association of these proteins by
Figure 2. pUL133, pUL135, and pUL136 localize to the Golgi apparatus. Fibroblasts were mock-infected or infected with FIX recombinant
viruses expressing myc-tagged versions of pUL133, pUL135, pUL136, and pUL138 at an MOI of 2. Viral proteins were localized by indirect
immunoflurescence at 24 and 48 hpi using rabbit anti-myc antibody (71D10). A mouse monoclonal antibody specific to GM130 marks the Golgi and
DAPI marks the nuclei.
doi:10.1371/journal.ppat.1002444.g002
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PLoS Pathogens | www.plospathogens.org 4 December 2011 | Volume 7 | Issue 12 | e1002444Figure 3. pUL133, pUL135, and pUL136 are integral membrane proteins associated with microsomal membranes. (A) Linear diagrams
of indicated proteins. Amino acid positions of putative TM domains are indicated by black boxes. TM domains were predicted by multiple algorithms
as part of the Mac vector software suite. The myc epitope tag on pUL136 is indicated. (B) To determine the membrane association of each viral
protein, MRC5 cells were mock infected or infected with FIX-UL136myc virus at an MOI of 1 were harvested at 44 hpi following 4h incubation with
cycloheximide. Crude membrane fractions were prepared by differential centrifugation at the speeds indicated and analyzed for specific proteins by
immunoblotting using rabbit polyclonal antibodies specific to each viral protein and the mouse monoclonal antibody specific to the myc epitope tag.
(C) To determine if the viral proteins were integral membrane proteins, 25K microsomal membrane fractions were treated with 100 mM Na2CO3 for
1 h on ice and pelleted at 100,0006g for 1 h at 4
oC. Equal amounts of input, pellet and supernatant were analyzed for specific proteins by
immunoblotting as above. (D) To determine the topology of proteins in the Golgi membranes, 25K microsomal membrane fractions were treated
with 0.5 mg/ml proteinase K for 45 min at 37uC in the presence or absence of 1% Triton X-100. Viral proteins were detected by immunoblotting as
described above. MHC I was used as a control in panels B–D.
doi:10.1371/journal.ppat.1002444.g003
Novel HCMV UL133-UL138 Locus
PLoS Pathogens | www.plospathogens.org 5 December 2011 | Volume 7 | Issue 12 | e1002444analyzing crude membrane preparations from MRC5 cells either
uninfected or infected with FIX-UL136myc at an MOI of 1. Cells
were treated with cycloheximide 4 hours prior to harvest to allow
newly synthesized proteins to traffic to their resident compart-
ments. 3K and 12K fractions contain cytoplasmic and nuclear
membranes, respectively, whereas the 25K and 100K pellet
fractions contain lighter vesicles and microsomal membranes. The
100K supernatant contains soluble proteins. Proteins were
detected in each fraction using the myc antibody to detect
pUL136 or polyclonal antibodies to each HCMV protein. The
major histocompatability complex I (MHC I) protein was analyzed
as a control using a monoclonal antibody. Similar to pUL138,
pUL133 and pUL135 were concentrated in the 25K and 100K
pellets indicating their association with lighter microsomal
membranes (Figure 3B). This data is consistent with the
localization of these proteins to the Golgi (Figure 2). pUL133,
pUL135 and pUL138 also accumulated in the 3K pellet
representing heavier membranes. This broad distribution may
reflect trafficking of these proteins through the secretory pathway
and is similar to the distribution of MHC I.
pUL136-20K was predominantly associated with the 100K
supernatant, suggesting that this is a cytosolic protein. Consistent
with this finding, we have previously demonstrated that smaller
truncated forms of pUL136 are expressed from the 1.4-kb UL138
transcript, which begins 300 nucleotides downstream of the full-
length UL136 start codon and lacks a predicted TM domain [22].
The pUL136-27K protein was associated with the 25- and 100-K
pellets as observed for pUL133, pUL135, and pUL138, suggesting
that this protein contains the N-terminal portion of the protein,
including the transmembrane domain. The predicted molecular
mass of the full-length pUL136 protein based on amino acid
sequence is 27-kDa. Intriguingly, we did not detect pUL136-37k in
experiments with a cycloheximide chase. This may be due to the
low abundance and/or the narrow window of expression of this
protein (Figure 1C). Alternatively, this result may be due to the
rapid turnover of the protein or the sensitivity of a modification
resulting in the 37-kDa mass to cycloheximide treatment.
The predicted TM domains for pUL133, pUL135, and full
length pUL136 are in the N-terminus of each protein, as is the
case for pUL138 (Figure 3A). In order to determine if pUL133,
pUL135, and pUL136-27k are integral membrane proteins, we
treated 25k microsomal membrane fractions with buffer contain-
ing 100mM sodium carbonate (Na2CO3), which is typically used
to disrupt protein-protein interactions without affecting protein-
lipid interactions. Following salt extraction, the pellet and the
supernatant were analyzed by immunoblotting using antibodies as
described for Figure 3B. pUL133, pUL135 and pUL136-27k were
resistant to Na2CO3 extraction and recovered exclusively in the
pellet (Figure 3C), indicating that these proteins are integral
membrane proteins similar to pUL138 and MHC I [19].
To determine the orientation of pUL133, pUL135, and
pUL136 in membranes, 25k microsomal membrane fractions
from cells infected with FIX-UL136myc were treated with
proteinase K in the presence or absence of 1% Triton-X100.
Lysates were analyzed by immunoblotting as described previously
for Figure 3B (Figure 3D). Approximately 50% of MHC I was
digested by proteinase K under native conditions to yield a lower
molecular mass band as previously reported [19,23,24]. MHC I
was completely converted to the lower molecular mass form in the
presence of detergent. As previously reported, pUL138 associated
with microsomal membranes was efficiently digested (60–90%) in
the absence of detergent [19]. Similarly, proteinase K treatment of
microsomal membranes resulted in efficient digestion of pUL133
(60–90%), pUL135 (80–90%), and pUL136 (95–100%) in the
absence of detergent as observed in four independent experiments.
The predicted N-terminal position of the TM domains for each of
these proteins and the near complete digestion of these proteins in
the absence of detergent suggest that, like pUL138, the large C-
terminal domains of each protein is exposed on the cytosolic face
of Golgi membranes. The less efficient digestion of pUL133 may
be related to the possibility that pUL133 may span the membrane
twice. Given that the majority of pUL133 is digested, we interpret
these results to indicate that both the N- and C-termini of pUL133
are on the cytosolic face of 25K fraction membranes. The
membrane association and the topology for each of these proteins
were unchanged when expressed individually by lentivirus
transduction (Figure S2). The observed topology of these proteins
in Golgi membranes likely has important implications for their
function during infection. Taken together, these data demonstrate
that the three proteins, pUL133, pUL135, and pUL136 expressed
with pUL138 from polycistronic transcripts have similar properties
to pUL138 with regard to localization and membrane association.
The UL133-UL138 locus is dispensable for productive
infection in fibroblasts
To address the significance of the UL133-UL138 locus in viral
infection, we constructed a recombinant virus in the TB40E strain
that lacks the entire UL133-UL138 locus termed TB40E-UL133-
UL138NULL (Figure 4A). The TB40E virus strain was used for
these studies to analyze the role of the UL133-UL138 locus in
infection as TB40E exhibits broader tropism than the FIX strain.
MRC5 cells were infected with the parental TB40E strain
(TB40E-WT) or TB40E-UL133-UL138NULL at an MOI of 0.2.
Viral replication was measured over a time course by TCID50
(Figure 4B). As would be expected for viruses lacking ULb9
Figure 4. Construction and characterization of the TB40E-
UL133-UL138NULL virus. (A) Schematic of ULb9 locus encoding the
UL133-UL138 locus and UL133-UL138NULL recombinant virus in which
UL133-UL138 locus replaced by Galk (black arrow) is shown. ORFs are
designated by arrows. (B) To examine the replication kinetics of the
TB40E-UL133-UL138NULL virus relative to the TB40E-WT virus, MRC5 cells
were infected at 0.2 MOI and virus titers measured by TCID50 over the
time course indicated.
doi:10.1371/journal.ppat.1002444.g004
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and to yields similar to TB40E-WT. Not unexpectedly, TB40E-
UL133-UL138NULL also replicated to similar yields as the wild-
type virus at high MOI (Figure S3A). The analogous virus was also
made in the FIX strain of HCMV and this virus also replicated to
similar yields as the wild-type virus (Figure S3B). These results
indicate that the UL133-UL138 locus is dispensable for viral
replication in fibroblasts.
Colocalization of pUL133, pUL135, pUL136, and pUL138
during productive infection
Since each protein from the UL133-UL138 locus localized to the
Golgi (Figure 2), we next wanted to determine the extent to which
the proteins co-localize in the context of productive infection.
MRC5 cells were infected with TB40E-UL133-UL138NULL at an
MOI of 2 to provide the context of viral infection. At 6 hpi, cells
were then co-transduced for 48 h with four lentivirus contructs
expressing pUL133, pUL135, pUL136, and pUL138, each with a
different carboxy terminal epitope tag. Antibodies specific to the
Flag (FLAG), hemagglutinin (HA), myc, or glu-glu (EE) epitope
tags were conjugated with Quantum dots and used to label
pUL133FLAG, pUL135HA, pUL136myc, and pUL138EE, respec-
tively. When expressed independently, pUL133FLAG, pUL135HA,
pUL136myc, and pUL138EE localized in part to a perinucler
region resembling the Golgi, implying that the localization of these
proteins to the Golgi did not require other viral proteins or the
context of infection (Figure S4). Similar to infection (Figure 2),
both pUL133FLAG and pUL135HA exhibited a more diffuse
localization showing both cell surface and perinuclear staining
resembling the Golgi (Figure S4). Importantly, Figure S4
demonstrates that there was no appreciable background or bleed
through of these signals in each of the five channels.
When expressed together, there was substantial overlap in the
signals for all four proteins (Figure 5). Due to the high level of
pUL133FLAG expression, merged images are shown of all viral
proteins with and without pUL133FLAG. pUL136myc and
pUL138EE exhibited the greatest overlap in their localization
pattern. There were some notable differences in staining where
pUL135HA appears to be excluded from perinuclear regions
strongly stained with pUL133FLAG and pUL138EE. It is interesting
that regions of pUL135HA staining are typically juxtaposed to
regions of intense pUL133FLAG and pUL138EE staining. Impor-
Figure 5. Colocalization of pUL133, pUL135, pUL136 and pUL138 in the Golgi apparatus. MRC5 cells were infected with TB40E-UL133-
UL138NULL and co-transduced with lentiviruses encoding pUL133FLAG, pUL135HA, pUL136myc, and pUL138EE or an empty lentivirus at an MOI of 2.
Proteins were co-localized by direct immunofluorescence 48 hpi using monoclonal antibodies specific to each epitope tag that had been directly
conjugated to Quantum dots of 525nm (HA); 565nm (Myc); 585nm (FLAG); and 625nm (EE). Cell nuclei are indicated by Qnuclear staining. Localization
was visualized using a Ziess 510 Meta Confocal microscope. Images for five representative cells are shown in the five rows below empty.
doi:10.1371/journal.ppat.1002444.g005
Novel HCMV UL133-UL138 Locus
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empty vector, demonstrating the specificity of the antibodies and
that these antibodies were not bound by viral Fc receptors. The
significance of these patterns and regions of overlapping and non-
overlapping protein localization awaits further investigation.
Expression of the UL133-UL138 locus in CD34
+ HPCs
Given the role of pUL138 in latency, the other proteins
expressed from the UL133-UL138 locus may function to cooperate
with pUL138 in establishing a latent infection in CD34
+ cells. We
first analyzed protein expression from the UL133-UL138 locus in
infected CD34
+ HPCs. CD34
+ HPCs, freshly isolated from
umbilical cord blood were infected with TB40E-WT or TB40E-
UL136myc at an MOI of 2. Pure populations of infected (GFP
positive) CD34
+ cells were isolated by fluorescent activated cell
sorting (FACS) and seeded into long-term bone marrow cultures
(LTBMC) over a stromal support. Whole cell lysates were
prepared at 2 and 5 days post infection (dpi) and analyzed for
protein expression by immunoblotting using polyclonal antisera to
HCMV proteins, the monoclonal antibody specific to IE1 and
IE2, or a monoclonal antibody recognizing the myc epitope tag.
Representative blots are shown from five independent experi-
ments. We detected transient expression of IE1, which did not
persist past 2 dpi (Figure 6A). IE1 transcript expression in HPCs
has been detected previously [19,25,26]. Similarly, pUL133 was
detected at 2 dpi but not at 5 dpi. As previously observed, pUL138
was expressed in CD34
+ HPCs at 2 and 5 dpi [19]. By contrast, we
detected very low to undetectable levels pUL135 or pUL136 in
these cells under conditions where the expression of pUL138 was
readily detected. While we cannot exclude the possibility that
pUL135 and pUL136 are expressed in CD34
+ HPCs, their
relative abundance is substantially diminished compared to
infected fibroblasts and we consistently fail to detect these proteins
in CD34
+ HPCs with our current tools. These results indicate that
expression of individual proteins from the UL133-UL138 locus
may be differentially modulated based on the context of infection.
Given the low levels of expression of pUL135 and pUL136
detected in CD34
+ HPCs, it is uncertain as to what role these
Figure 6. UL133-UL138 locus expression in CD34
+ HPCs. CD34
+ HPCs infected with TB40E-WT or TB40E-UL136myc at MOI 2.0. Pure populations
of infected CD34
+ cells were maintained in LTBMC. (A) Lysates prepared from equal cell numbers at 2 and 5 days post infection (dpi) were analyzed by
immunoblotting using either mouse anti-myc antibody to detect pUL136 or rabbit polyclonal antibodies directed against pUL133, pUL135, or
pUL138. b-actin was used as a loading control. (B) RNA isolated from infected CD34
+ HPCs was analyzed at 2 dpi by qRT-PCR. The relative target levels
for UL133, UL135, UL136, and UL138 transcripts were determined using the DDCT equation and are expressed here as a fold over b-actin that was used
as an internal reference. The ratio of 3.6-, 2.7-, and 1.4-kb transcripts is indicated. A schematic representative of the relative abundance of each
transcript is shown. The bars represent an average of three replicates where the standard deviation is shown.
doi:10.1371/journal.ppat.1002444.g006
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latency.
The differential expression of UL133-UL138 locus proteins in
CD34
+ cells may be due to the relative abundance of transcripts
encoding pUL138. As we have shown previously, pUL138 can be
expressed from 3.6-, 2.7-, and 1.4-kb transcripts, although it
appears to be most efficiently expressed from the 1.4-kb transcript
[22]. By contrast, pUL133 and pUL135 are expressed only from
the 3.6- and 2.7-kb transcripts, respectively. We reasoned that if
the 1.4-kb transcript was expressed more abundantly in CD34
+
HPCs than the 3.6- and 2.7-kb transcripts, this could explain the
enhanced levels of pUL138 expression. RNA was isolated from
infected CD34
+ HPCs at 2 dpi and the 3.6-, 2.7-, and 1.4-kb
transcripts were quantitated by real time reverse-transcriptase
PCR (qRT-PCR) using primers specific to UL133, UL135, UL136
or UL138. As a control, we used TB40E-UL133-UL138NULL
where none of these transcripts are expressed. We detected
significant levels of 3.6-, 2.7- and 1.4-kb transcripts compared to
control infection. Transcript levels of IE1 and IE2 were nearly
identical in cells infected with both TB40E-WT and TB40E-
UL133-UL138NULL (fold change of 1.3 and 1.4, respectively; data
not shown). The 3.6-, 2.7-, and 1.4-kb transcripts were present in
1:3:3 ratio, respectively (Figure 6B). While these results could
explain the higher level of pUL138 expression, they do not explain
the absence of pUL135 and pUL136 since the ratio of 2.7- to 1.4-
kb transcripts is 1. Therefore, translational regulation of these
transcripts may also play a role in protein abundance.
The UL133-UL138 locus suppresses viral replication in
CD34
+ HPCs
We next sought to determine the role of the UL133-UL138 locus
in latency. We have previously demonstrated a role of pUL138 in
the FIX strain for promoting the latent infection [18,19]. For a
relative comparison, we generated a virus using the TB40E strain,
TB40E-UL138Stop, where UL138 was disrupted by the substitution
of the initiator codon with a stop codon. Further, as pUL133
expression was reliably detected in infected CD34
+ HPCs
(Figure 6A), we generated a virus containing a similar disruption
in UL133. We analyzed the replication of these recombinants
relative to TB40E-WT in MRC5 cells using multi-step growth
curves (Figure 7A). Similar to FIX strains containing disruptions in
UL138, TB40E-UL133Stop and TB40E-UL138Stop replicated with
slightly enhanced yields relative to TB40E-WT [19]. These results
demonstrate that UL133, like UL138, is dispensable for viral
replication in fibroblasts.
To analyze latency, CD34
+ HPCs were infected with TB40E-
WT, TB40E-UL133-UL138NULL, TB40E-UL133Stop, or TB40E-
UL138Stop at an MOI of 2. Pure populations of infected CD34
+
cells were incubated in LTBMC for 10 dpi. Cell lysates were
analyzed by an infectious centers assay to determine the number of
cells required to form an infectious center [18,26]. This assay is a
measure of virus replication, but distinct from a plaque forming or
TCID50 assays. The infectious centers assay is appropriate for
these measures because each infected CD34
+ HPC does not go on
to produce virus upon reactivation. It is thought that the
differences between viruses with regards to the establishment of
or reactivation from latency is the number of infected cells
producing virus as opposed to the yield of virus per cell [18,26].
TB40E-UL133-UL138NULL (p=0.0043), TB40E-UL133Stop
(p=0.0005), and TB40E-UL138Stop (p=0.0143) replicated with
increased efficiency in HPCs relative to the wild type virus
(Figure 7B), producing 5-fold greater infectious centers compared
to cells infected with the wild-type virus. Similar to previous
findings for UL138, these data suggest a role for UL133, UL138,
and the entire UL133-UL138 locus in suppressing viral replication,
presumably for the latent infection in HPCs [18,19]. Further work
is required to determine the individual contributions of these and
other UL133-UL138 locus proteins to viral replication or latency in
this model.
The UL133-UL138 locus is required for efficient viral
replication in primary endothelial cells
HCMV infects a wide array of cell types in the human host.
ULb9 genes are predicted to encode functions that mediate viral
replication, dissemination, and persistence in the host. To
determine if the UL133-UL138 locus is important for viral
replication in other cell types, we compared viral yields in
endothelial and epithelial cells infected with TB40E-WT or
TB40E-UL133-UL138NULL (Figure 8A). We chose 3 different
primary human endothelial cell types (microvascular lung,
HMVEC; umbilical vein, HUVEC; aortic, HUAEC), one
endothelial cell line (HAEC), and one primary human renal
epithelial cell type HRCE. In each case, cells were infected with an
MOI of 0.1 and cell lystates were harvested 10 dpi. Surprisingly,
TB40E-UL133-UL138NULL exhibited a modest to severe replica-
tion defect (5–200 fold) in all endothelial cell types analyzed. By
comparison, TB40E-UL133-UL138NULL replicated similarly to
TB40E-WT in the epithelial cell type tested.
To further explore the role of the UL133-UL138 locus in
endothelial cells, we analyzed multi-step replication of UL133-
UL138NULL in HMVECs. HMVECs were infected with TB40E-
WT, TB40E-UL133-UL138NULL or TB40E-UL138Stop at an
MOI of 0.2 and whole cell lysates analyzed for virus production
over a time course following infection by TCID50 (Figure 8B).
TB40E-UL133-UL138NULL exhibited a 2-log defect in replication
relative to TB40E-WT. This defect in replication was not due to a
failure of the mutant virus to enter or spread in HMVEC cells
based on the initial number of infected (GFP
+) cells and the
formation of plaques, respectively (data not shown). Further, this
defect cannot be overcome by infecting cells at higher multiplic-
ities (MOI of 2; data not shown). Viruses lacking only UL138
exhibited no defect relative to TB40E-WT, suggesting pUL138 is
not required for replication in these cells.
We next analyzed protein expression from the UL133-UL138
locus in endothelial cells. HMVECs were infected at an MOI of 2
and whole cell lysates were analyzed for pUL133, pUL135,
pUL136 and pUL138 expression at 2 and 5 dpi by immunoblot-
ting. As a control for infection, we analyzed the expression of the
IE1 and IE2 proteins. We detect IE1 in HMVECs, but IE2 is
consistently expressed at low to undetectable levels in these cells
(Figure 8C). With regards to the UL133-UL138 locus, we readily
detected expression of pUL135 and pUL138 at 2 dpi. pUL133 was
detected, but only at the 5 dpi time point. Expression of pUL136
was undetectable in each of three independent infections. The
failure to detect pUL136 may be due to the variability in
expression of the pUL136 isoforms or in the inherent instability of
pUL136 (Cicchini and Goodrum, unpublished results).
The UL133-UL138 locus modulates virus reactivation and
dissemination in vivo
Given the three cell type-dependent replication phenotypes
associated with the UL133-UL138 locus, we analyzed viral
replication and dissemination in a NOD-scid IL2Rcc
null-human-
ized mouse model. This model represents the only animal model
to effectively study HCMV infection parameters including of
latency and reactivation [27]. NOD-scid IL2Rcc
null mice were
engrafted with human CD34
+ HPCs. The huCD34
+-engrafted
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WT or TB40E-UL133-UL138NULL or uninfected fibroblasts as a
negative control (8 mice per experimental group). At 4 weeks post
infection, four mice in each group were treated with granulocyte-
colony stimulating factor (G-CSF) and AMD-3100 to induce stem
cell mobilization and viral reactivation. At two weeks post
mobilization, we measured viral genome loads in bone marrow
and spleen tissues by quantitative TaqMan PCR with probes and
primers specific for HCMV US28.
HCMV genomic DNA was detected in the bone marrow of
both wild type and UL133-UL138NULL infected non-mobilized
mice (351 copies/mg DNA for TB40E-WT vs. 291 copies/mg for
TB40E-UL133-UL138NULL; p=0.17; not significant) and did not
increase significantly upon mobilization (Figure 9A). Both viruses
showed an increase in splenic viral DNA loads following
mobilization suggesting that cells infected with both viruses were
disseminated to the spleen (Figure 9B). However, mobilization of
the mice infected with TB40E-UL133-UL138NULL resulted in a 2-
to 3-fold higher levels of viral DNA load in the spleen compared to
wild-type-infected animals (p=0.08). Mice infected with TB40E-
WT had an overall 1.4-fold increase in spleen viral DNA load
following mobilization versus a 43-fold increase in TB40E-UL133-
UL138NULL infected mice. Low levels of viral DNA were detected
in the spleens of unmobilized mice infected with either TB40E-
WT or UL133-UL138NULL because infected cells do not efficiently
traffic out of the bone marrow in the absence of mobilization.
These data indicate that the UL133-UL138 locus is important for
modulating viral replication, reactivation or dissemination in this
model.
The UL133-UL138 locus encodes proteins unique to
human and chimpanzee CMV
In an effort to understand the possible function of the proteins
encoded from the UL133-UL138 locus, we searched the known
protein sequence databases for protein sequence similarity using
BLASTpsi (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Further, we
used PHOG (http://phylofacts.berkeley.edu/orthologs/) to pre-
dict super-orthologs based on phylogenetic analysis [28]. Finally,
Figure 7. UL133-UL138 locus function in CD34
+ HPCs. (A) Multistep growth curves for TB40E recombinant viruses. Fibroblasts were infected at
0.2 MOI and virus titers measured by TCID50 over the time course indicated. (B) CD34
+ HPCs infected with TB40E-WT, TB40E-UL133-UL138NULL, TB40E-
UL133Stop or TB40E-UL138Stop viruses at MOI 2.0. Pure populations of infected CD34
+ cells were maintained in LTBMC for 10 dpi after which lysates
from infected CD34
+ HPCs were serially diluted onto MRC5 cells plated in 96 well dishes. Infectious centers formation was determined from the
number of GFP
+ wells at each dilution 15–20 days later. The frequency of infectious centers was calculated using ELDA software. The data shown is an
average of three independent experiments. TB40E-UL133-UL138NULL, TB40E-UL133Stop and TB40E-UL138Stop viruses replicated with 5-fold greater
efficiency compared to TB40E-WT (p=0.0043, p=0.0005 and 0.0148, respectively).
doi:10.1371/journal.ppat.1002444.g007
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three dimensional structure using homology modeling, which does
not rely on conservation of protein sequence [29]. No cellular or
viral homologs were identified by any of these bioinformatics
methods for any of the UL133-UL138 locus cds with the exception
of HHV-5/CMV orthologues (data not shown). Further, no
protein structures could be predicted.
Due to the lack of identifiable protein structure, we next
analyzed these proteins for regions of disorder using Disopred2
(http://bioinf.cs.ucl.ac.uk/disopred). This algorithm predicted
large regions of disorder across pUL133, pUL135, pUL136 and
pUL138 suggesting that these are intrinsically disordered proteins
(data not shown). Intrinsically disordered proteins typically adapt
structure through their interactions and often interact with a large
number of proteins [30]. These analyses indicate that the UL133-
UL138 locus proteins are unique to CMV and, as such, will
require further molecular and biochemical studies to understand
their role in infection.
To determine the extent of conservation of the UL133-UL138
locus within CMV orthologues, we aligned the ULb9 sequences
available from NCBI for HCMV (strain TB40E; Accession:
EF99921.1; GI: 157779983), ChCMV (strain heberling; Acces-
sion: NC_003521.1; GI: 20026600) and RhCMV (strain 68-1;
Accession: NC_006150.1; GI: 51556461) (Figure 10). Of note,
sequences with similarity to the ULb9 region were identified only
in ChCMV and RhCMV and not in any CMVs of lower
mammals for which a sequence is known. Orthologues to each
gene encoded within the UL133-UL138 locus are present in
ChCMV. The ChCMV orthologues for the strains aligned share
44.2%, 46.7%, 53.8% and 56.7% similarity at the amino acid level
with pUL133, pUL135, pUL136, and pUL138, respectively. In
RhCMV, the ULb9 region is positionally conserved. However, few
RhCMV genes in this region share substantial sequence identity
with HCMV ULb9 genes [31]. RhCMV Rh166 ORF shows
similarity to both HCMV pUL133 (26.6%) and pUL138 (35%). In
addition, the RhCMV Rh171 ORF also shows similarity to
HCMV pUL133 (27.6%). Hence, Rh166 and Rh171 might
represent the orthologues for HCMV pUL138 and pUL133,
respectively, though the exact corresponding homologues are not
clear from the analyses performed. No significant identity between
UL135 and UL136 of HCMV and RhCMV proteins was
observed.
Figure 8. Expression and function of UL133-UL138 locus in primary endothelial cells. (A) Four endothelial cell types (HMVEC, HUVEC,
HUAEC or HAEC) and one epithelial cell type (HRCE) were infected with TB40E-WT or TB40E-UL133-UL138NULL at MOI 0.1. At 10 dpi, virus titers in
lysates were determined by TCID50 on MRC5 cells. (B) HMVEC-L cells infected with TB40E-WT, TB40E-UL133-UL138NULL or TB40E-UL138Stop at MOI 0.1
were harvested at indicated times post infection to analyze multi-step replication. Virus titers were determined by TCID50 on MRC5 cells. (C) HMVEC
cells infected with TB40E-WT or TB40E-UL136myc at MOI 2.0 were harvested at 2 and 5 days post infection (dpi) and lysates prepared from equal
numbers of cells were analyzed by immunoblotting using either mouse anti-myc antibody to detect pUL136 or rabbit polyclonal antibodies directed
against each UL133-UL138 locus protein.
doi:10.1371/journal.ppat.1002444.g008
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We have identified and characterized a novel locus within the
ULb9 region of the HCMV genome that encodes three proteins,
pUL133, pUL135, and pUL136, in addition to the pUL138
latency determinant [22]. The pUL133, pUL135, and pUL136
proteins have not been previously characterized. Proteins encoded
by the UL133-UL138 locus predominantly localize to Golgi
membranes (Figure 2, 3 and 5) with large C-terminal domains
exposed on the cytosolic face of the membranes (Figure 3). UL133-
UL138 locus proteins exhibit overlapping localization, but did not
completely co-localize (Figure 5). The profile of expression of the
individual proteins from the UL133-UL138 locus varied substan-
tially depending on the context of infection (Figure 1C–D, 6A,
8C). As would be expected for ULb9 sequences, the UL133-UL138
locus was dispensable for viral replication in fibroblasts (Figure 4
and S3). Disruption of the UL133-UL138 locus resulted in a virus,
UL133-UL138NULL, with increased frequency of infectious centers
formation in CD34
+ HPCs relative to the wild-type virus
(Figure 7B), consistent with a failure to establish a latent infection.
Intriguingly, UL133-UL138NULL exhibited a severe replication
defect in primary human endothelial cells (Figure 8A and 8B).
These three distinct context-dependent phenotypes indicate that
the UL133-UL138 locus may mediate context-dependent out-
comes of infection. The mechanism by which the UL133-UL138
locus contributes to cell-type dependent outcomes of infection
awaits further investigation. Importantly, UL133-UL138NULL
exhibited increase replication and dissemination in a NOD-scid
IL2Rcc
null-humanized mouse model (Figure 9), indicating a role
for this locus in mediating viral replication, latency or dissemina-
tion in vivo. Further, as the UL133-UL138 locus is unique to CMV
strains of higher order primates, we predict that these proteins
represent viral adaptations to infection and persistence in the
primate host (Figure 10).
The ULb9 region of the HCMV genome was first recognized
over a decade ago [15]. As this region is unique to CMV strains
infecting primates and is dispensable for viral replication in
fibroblasts, the most common model for productive viral
replication, it presents significant challenge for research and has
been understudied. The genes in this region are postulated to
encode viral adaptations to the host, involved in immune evasion,
pathogenesis, or viral persistence or latency. The coding potential
of genes in the ULb9 region has been shown for only a few of the
20 putative ORFs. These include UL138, UL141, UL142, UL144,
and UL146. UL138 encodes a protein that is required, but not
sufficient, for the latent infection in HPCs infected in vitro [18,19].
It has been recently demonstrated that pUL138 functions to
regulate cell surface levels of TNFR [20,21]. UL141 [32] and
UL142 [33] encode proteins to evade elimination by natural killer
cells. UL142 is expressed late in infection and encodes a MHC
class I related molecule, which renders the cells resistant to NK
mediated cell lysis. UL144 functions as a tumor necrosis factor
(TNF) homolog that activates NFKB, which in turn enhances the
expression of CCL22, a chemokine, which attracts Th2 and T
regulatory cells. Thus UL144 may help the virus evade immune
surveillance by enhancing the Th2 response while subverting the
Th1 response [34,35]. UL146 encodes a viral CXCL chemokine
that binds the IL-8 receptor to enhance neutrophil chemotaxis and
degranulation [36]. Another putative CXC homologue, UL147,
has been identified [36]; however, the coding potential of this
ORF and its function has not been explored. Most recently, we
have extended our studies on pUL138 to characterize the protein
coding capacity of the UL133, UL135, and UL136 ORFs, encoded
on polycistronic transcripts with UL138 [22]. The individual
functions of pUL133, pUL135, and pUL136 have not yet been
determined. The sequence analyses of these proteins do not
indicate any obvious sequence motifs or functional domains that
suggest protein function. The fact that these proteins share similar
cellular and biochemical properties (Figure 2, 3 and 5) to that of
pUL138 suggests that they may function together during infection.
We hypothesize that these proteins may function with pUL138 in
modulating the outcome of infection in a context dependent
manner. Our ongoing research focuses on determining the
functions of each of these proteins during HCMV infection.
Figure 9. Analysis of UL133-UL138NULL infection in humanized
mice. NOD-scid IL2Rcc
null mice were engrafted with human CD34
+
HPCs and then transfused with human fibroblasts infected with TB40E-
WT or TB40E-UL133-UL138NULL virus. Uninfected mice served as negative
controls (n=4). At 4 weeks post infection, mice were treated with G-CSF
and AMD-3100 or left untreated (n=4/group) for two weeks and then
euthanized for tissue harvesting and analysis. Total genomic DNA was
isolated from (A) bone marrow or (B) or spleen and analyzed for the
presence of viral DNA by quantitative PCR using primers and probe
specific for HCMV-US28. Data is represented as viral DNA copy number/
mg of total DNA. Viral DNA loads in the bone marrow for WT and UL133-
UL138NULL infections were nearly equal (p=0.17 and 0.18 for
unmobilized and mobilized mice, respectively). Viral loads in the spleen
were greater in the mobilized UL133-UL138NULL-infected mice compared
to mobilized WT-infected mice (p=0.08) and compared to the
unmobilized UL133-UL138NULL-infected mice (p=0.001).
doi:10.1371/journal.ppat.1002444.g009
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identity only with other HHV-5 orthologues. While the proteins
encoded by the UL133-UL138 locus are conserved in chimpanzee
CMVs, orthologues have not been identified in cytomegalovirus
strains infecting lower mammals, including RhCMV and MCMV
[31]. In RhCMV, the ULb9 region is positionally conserved, but
few proteins have considerable sequence identity (Figure 10) [31].
Both UL133 and UL138 share moderate similarity to rh166 while
UL133 also shows weak homology to rh171. We propose, given the
position of the Rh166 and Rh171 ORFs and the moderate
conservation of sequence, that these ORFs represent orthologues
of pUL133 and pUL138 of HCMV. No orthologues were
identified for pUL135 or pUL136, as previously reported [31].
These observations suggest that UL133-UL138 locus resulted from
co-speciation in higher order primates, and suggest an intriguing
possibility that these proteins engage in virus-host interactions that
are highly adapted to the host species.
Our studies indicate, as would be expected for ULb9 sequences,
that the UL133-UL138 locus was dispensable for replication in
cultured fibroblasts (Figure 4). However, the locus augmented
replication in primary endothelial cells (Figure 8) and impeded
replication in CD34
+ HPCs (Figure 7B). Further, profiles of gene
expression from the UL133-UL138 locus varied depending on the
cell type infected (compare Figure 1C and D to 6A and 8C). For
example, pUL135 was not detected in CD34
+ HPCs, but was
expressed efficiently in endothelial cells and fibroblasts, while
pUL136 could not be detected in endothelial cells of CD34
+
HPCs. This finding suggests that the ultimate outcome of infection
may rely on the profile of protein expression from the UL133-
UL138 locus in individual contexts of infection. As pUL135 and
pUL136 are not expressed in HPCs, they may not be required for
establishing or maintaining latency, but may function in some
other aspect such as reactivation.
Interactions between proteins encoded by the UL133-UL138
locus or with unique cell-type dependent host factors may underlie
the role of this locus in mediating cell-type specific infection
outcomes. Preliminary studies aimed at understanding the
function of UL133-UL138 locus proteins have revealed a complex
network of interactions and positive and negative acting proteins
(Umashankar, Petrucelli, Rak, and Goodrum, unpublished
results). The localization of UL133-UL138 locus proteins to the
Golgi (Figure 2 and 5) and their orientation in the membranes
(Figure 3) is certainly foretelling of the function of these proteins.
Proteins localized in the Golgi may play critical roles in viral
assembly and egress, protein trafficking, apoptosis [37,38], and the
cellular stress response [38]. Accordingly, the recently defined role
of pUL138 in modulating surface levels of TNFR, suggests that
pUL138 may mediate protein trafficking [20,21] and, therefore,
the cellular response to signaling molecules.
The conclusions drawn from our in vitro studies are bolstered by
our in vivo studies in humanized mice. The increased viral loads of
TB40E-UL133-UL138NULL virus in the spleens of NOD-scid
IL2Rcc
null-humanized mice following mobilization suggests in-
creased replication, reactivation or dissemination of this virus
relative to the WT virus (Figure 9B). This in vivo finding further
supports an important role for the UL133-UL138 locus in
suppressing replication or reactivation for latency. Mobilization
did not significantly increase WT or UL133-UL138NULL viral
genome copy number in the bone marrow (Figure 9A), possibly
reflecting the fact that mobilized cells quickly exit the bone
marrow. The fact that higher genome levels were not measured in
the bone marrow of UL133-UL138NULL-infected mice relative to
WT-infected mice prior to mobilization, suggests that these viruses
may not behave differently in this system in the absence of a
reactivation stimulus. The nature of the humanized mice studies is
such that the results cannot completely recapitulate our in vitro
studies, yet they are highly consistent with our in vitro studies, both
studies suggesting an important role for the UL133-UL138 locus in
modulating the outcomes of infection. Future studies into the
UL133-UL138 locus promise to reveal intriguing virus-host
interactions unique to higher-order primates mediating viral
persistence.
Materials and Methods
Ethics statement
Human cord blood was obtained from donors at the University
Medical Center at the University of Arizona using a protocol
approved by the Institutional Review Board. These specimens are
completely deidentified and provided to our research group as
Figure 10. Orthologues to UL133-UL138 locus proteins. The ULb9 region from HCMV, ChCMV, and RhCMV were aligned to identify orthologues
of pUL133, pUL135, pUL136, and pUL138. Conserved orthologues of ChCMV and RhCMV are shown with black arrows.
doi:10.1371/journal.ppat.1002444.g010
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out in strict accordance with the recommendations of the
American Association for Accreditation of Laboratory Animal
Care (AAALAC). The protocol was approved by the Institutional
Animal Care and Use Committee (number IS00001049) at
Oregon Health and Science University.
Cells
Human embryonic lung fibroblasts (MRC5) (purchased from
ATCC; Manassas, VA) were cultured at 37 uC in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 10 mM HEPES, 1 mM sodium pyruvate,
2 mM L-Glutamine, 0.1 mM Non-essential amino acids, 100 U/
ml penicillin and 100 mg/ml streptomycin. Human cord blood was
obtained from donors at the University Medical Center at the
University of Arizona using a protocol approved by the
Institutional Review Board. These specimens are completely
deidentified and provided to our research group as anonymous
samples. Mononuclear cells and CD34
+ HPCs were isolated and
cultured as previously described [19,22]. CD34
+ cells were
maintained in long-term culture as described previously [19] but
using MyeloCult H5100 (Stem Cell Technologies). The M2-10B4
murine stromal cell line expressing human interleukin-3 (IL-3) and
granulocyte-colony stimulating factor (G-CSF) and the S1/S1
murine stromal cell line expressing human IL-3 and stem cell
factor (SCF) (kind gift from Stem Cell Technologies on behalf of
D. Hogge, Terry Fox Laboratory, University of British Columbia,
Vancouver, BC) and cultured as recommended [39]. Primary
human microvascular lung endothelial cells (HMVEC), human
umbilical vein endothelial cells (HUVEC), human umbilical vein
endothelial cells (HUVEC), and human aortic endothelial cells
(HUAEC) were purchased from Lonza (Walkersville, MD).
HMVEC, HUAEC, HUVEC cells were cultured in EGM-2
MV (Microvasular Endothelial Cell Growth Medium-2; Lonza),
EGM-MV (Endothelial Growth Medium- MV; Lonza) and EGM
(Endothelial Growth Medium; Lonza). Human aortic endothelial
cells (HAEC) were a generous gift from Andrew Yurochko and
were cultured in EGM-2 (Endothelial Growth Medium-2; Lonza).
Human renal cortical epithelial cells (HRCE) were purchased
from Lonza (Walkersville, MD) and were cultured in REGM
(Renal Epithelial Cell Growth Medium; Lonza). All cells were
maintained at 37uC with 5% CO2.
Viruses
Recombinant bacterial artificial chromosomes (BACs) contain-
ing the HCMV genome were constructed in Escherichiae coli (E. coli)
by linear recombination in a two-step positive-negative selection
method that leaves no trace of the engineering process [19,40,41].
The green fluorescent protein (GFP) was engineered between
US34 and TRS1 in BAC clones of FIX [42,43] or TB40E [44]
virus strains as a marker of infection. In the first step, the SW102
E. coli strain containing the FIX or TB40E BAC were used to
insert a galk cassette between US34 and TRS1 genes. In the second
step, the galk cassette was replaced by an SV40-eGFP-BGH Poly-A
cassette PCR amplified from the pCMS-eGFP vector (Clonetech)
to generate the FIX or TB40E BACs used as the parental wild
type strains in all experiments herein. These variants replicate with
kinetics and to titers identical to the parental strains (data not
shown). Further recombinant viruses were generated by repeating
the insertion and substitution of galk using a PCR product flanked
by homologous viral sequences as described previously [19,22].
Oligonucleotide primers used for BAC recombineering are
described in Table 1. Recombinant viruses were screened by
BAC digestion, PCR, and sequencing. Virus stocks were
propagated, stored and titered as described previously [19].
Plasmids
Oligonucleotide primers used for making expression plasmids
are described in Table 2. The UL133, UL135 and UL136 ORFs
were PCR amplified using ORF specific primers flanked by a NheI
site on the forward primer and a BamHI site on the reverse
primer. The reverse primer contained the myc epitope tag
sequence to generate 39 tagged versions of each gene. The PCR
products were cloned into the NheI and BamHI sites of the pCIG2
vector [22]. These constructs termed pCIG-UL133myc, pCIG-
UL135myc, and pCIG-UL136myc, express proteins with a C-
terminal myc epitope tag with a 5 amino acid linker between the
protein coding sequence and the myc tag. To obtain HA
(YPYDVPDYA), 3X-FLAG (DYKDDDDK), or Glu-Glu (E-E)
(EYMPME) (at the C-terminus) versions of these proteins, the
PCR products containing a specific epitope tag were cloned into
NheI and EcoRV sites of pCIG2 vector as above. The resulting
plasmids were named pCIG2-UL133FLAG-IRES-BLEO, pCIG2-
UL135HA-IRES-HYGRO, pCIG2-UL136myc-IRES-NEO, and
pCIG2-UL138EE-IRES-PURO. In these constructs, the eGFP
downstream of IRES was replaced by drug resistance markers
such as Hygromycin (HYGRO), Neomycin (NEO), Bleomycin
(BLEO) or Puromycin (PURO).
Lentivirus production
The plasmids were co-transfected with pLP1, pLP2 and
pVSVG plasmids (Invitrogen, CA) at 2:1:1:1 ratio into 293FT
cells using Lipofectamine 2000 (Invitrogen, CA). Culture super-
natants were harvested 48 hpi and concentrated at 17,000 rpm
using a SW28 rotor for 2 h at 4
oC. Pellets were resuspended in
IMDM containing 10% BIT9500 (Stem Cell technologies).
Lentiviruses were titered on fibroblasts using the TCID50 method.
Immunoblotting
Immunoblotting was performed as described previously [19].
Briefly, 10–15 mg of protein lysates were separated on 4–12%
NuPAGE Bis-Tris, (Invitrogen, CA) or 11% Bis-Tris gels by
electrophoresis and transferred to 0.45 mm polyvinylidene di-
fluoride (Immobilon-FL, Millipore, MA) membranes. The proteins
were immunoblotted using mouse a-myc (Cell Signalling) or rabbit
polyclonal antibodies directed against each protein (Open
Biosystems) and detected using fluorescently conjugated secondary
antibodies and the Odyssey infrared imaging system (Li-Cor, NE).
All antibodies used are listed in Table 3.
Indirect immunofluorescence
Immunofluorescence to localize viral and cellular proteins in
infected cells was performed as described previously [19]. Briefly,
fibroblasts (5610
4 cells/well in 24-well plates) were mock infected
or infected with recombinant viruses encoding myc epitope-tagged
pUL133, pUL135, pUL136 and pUL138 at an MOI of 2 for 24
and 48 h. Cells were fixed in 2% paraformaldehyde in PBS and
stained with a rabbit antibody specific to myc epitope tag and
visualized using a Zeiss 510 Meta confocal microscope (Carl Zeiss
Microimaging, Inc. NY). The nucleus was stained with 1 mg/ml
DAPI (49,6 9-diamidino-2- phenylindole) and GM130 was used as
a Golgi marker.
Direct immunofluorescence
Fibroblasts were seeded on to 12 mm glass cover slips in 24 well
plates one day prior to infection. The next day cells were mock
Novel HCMV UL133-UL138 Locus
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2. At 6 hpi, cells were transduced with lentiviruses containing
pCIG2-UL133FLAG-IRES-BLEO, pCIG2-UL135HA-IRES-
HYGRO, pCIG2-UL136myc-IRES-NEO, pCIG2-UL138EE-
IRES-PURO alone or in combination in the presence of 8 mg/
mL of Polybrene (Sigma-Aldrich, St. Louis, MO). Cells were
processed for direct immunofluorescence 48 hours later using the
same method used for indirect immunofluorescence except for the
primary antibody incubations, nuclear staining, and mounting.
Briefly, primary antibodies to the various epitope tags were
conjugated to amine derivatized Quantum Dots (Molecular
Probes, Invitrogen, Carlsbad, CA) of 525 nm (Anti-HA), 565 nm
(Anti-myc), 585 nm (Anti-FLAG), and 625 nm (Anti-EE) emission
wavelengths according to manufacturer’s instructions (Table 3).
Primary antibodies were incubated in PBS-T + 1% BSA overnight
at 4uC. Post staining, cells were washed 3 times in PBS-T and
nuclei stained with Qnuclear Deep Red Stain (Molecular Probes,
Invitrogen, Carlsbad, CA) according to manufacturer’s instruc-
tions. Coverslips were washed 3 times in PBS and mounted using
Qmount Qdot mounting media (Invitrogen) according to
manufacturer’s instructions. Cells were imaged using a Ziess 510
Meta Confocal Microscope as a lambda stack and unmixed using
the Zeiss 510 Meta software version 4.2 and images were
processed using ImageJ software, NIH (http://rsbweb.nih.gov/
ij/download.html).
Membrane fractionation and association
Microsome preparation was done as described previously [19].
Briefly, fibroblasts were either mock infected or infected with FIX-
UL136myc virus at an MOI of 1 for 48 h. Cells were treated with
50 mg/ml cycloheximide for 4 h prior to harvesting at 48 h post
infection. Cells were resuspended in buffer A (250 mM Sucrose,
50 mM triethanolamine, 1 mM EDTA, 6 mM magnesium
acetate, 50 mM potassium acetate and 1 mM dithiothreitol) and
gently sonicated 3 times for 10 sec on ice at 30 sec intervals.
Membranes were fractionated by differential centrifugation to
obtain membrane pellets at 30006g, 12,0006g, 25,0006g and
100,0006g. The supernatant obtained post 100,0006g was
precipitated using trichloroacetic acid (TCA). All pellets were
resuspended in identical volumes of buffer A and analyzed by
immunoblotting using protein specific antibodies (Table 3).
Table 1. Primers used to generate recombinant viruses.
Primer name Sequence (59 to 39)
FIX or TB40E-GFP-GalK-Fwd CGTGTCCTGGTTTTTCATTTTTTGGATGTATTTGTCGCA
TAAAAGGCGGTCCTGTTGACAATTAATCATCGGC
FIX or TB40E-GFP-GalK-Rev TGTTAGGATAACAAAACTGCGTATCTGGATATATTTCA
TCCCCACATCCCTCAGCACTGTCCTGCTCC
FIX or TB40E-GFP--Fwd CGTGTCCTGGTTTTTCATTTTTTGGATGTATTTGTCGCA
TAAAAGGCGGTGCAGCACCATGGCCTGAAAT
FIX or TB40E-GFP-Rev TGTTAGGATAACAAAACTGCGTATCTGGATATATTTCA
TCCCCACATCCCACCATACGCGGATCTGCC
TB40E-UL133-UL138NULL-Fwd ACTCGGCAGCCACTGTAGGGATAAATAGTGCGATGGC
GTTTGTGAGAGAACGCCTGTTGACAATTAATCATC
TB40E-UL133-UL138NULL-Rev TTCATTCTGGGGTTTCCCAATGACGTAAAAATTTCCAC
TACACAATAAAATCAGCACTGTCCTGCTCCTT
T40E-UL133Stop-GalK-Fwd CCACTGTAGGGATAAATAGTGCGATGGCGTTTGTGAG
AGAACGCAGTAGCGCCTGTTGACAATTAATCATCGGCA
T40E-UL133Stop-GalK-Rev GGAAGGAGATGTGGGCCAAGTCGGAAAATTCCTTATC
ACACCGGGGGCGGGTCAGCACTGTCCTGCTCCTT
T40E-UL133Stop-Fwd CCACTGTAGGGATAAATAGTGCGATGGCGTTTGTGAGA
GAACGCAGTAGCGTAAGGTTGAGACGTGCACGATCCTTCG
T40E-UL133Stop-Rev GGAAGGAGATGTGGGCCAAGTCGGAAAATTCCTTATCA
CACCGGGGGCGGGTTACGTTCCGGTCTGATGCTGCTGCTG
T40E-UL138Stop-GalK-Fwd CCATGGACGATCTGCCGCTGAACGTCGGGTTACCCATCA
TCGGCGTGCCTGTTGACAATTAATCATC
T40E-UL138Stop-GalK-Rev TCGTGCCAATGGTAAGCTAGATAGCAGAGAATGGCCAC
GATCAGCACGAGTCAGCACTGTCCTGCTCCTT
T40E-UL138Stop-Fwd CCATGGACGATCTGCCGCTGAACGTCGGGTTACCCAT
CATCGGCGTGTAACTCGTGCTGATCGTGGCCATTCTC
TGCTATCTAGCTTACCATTGGCACGA
T40E-UL138Stop-Rev TCGTGCCAATGGTAAGCTAGATAGCAGAGAATGGCCA
CGATCAGCACGAGTTACACGCCGATGATGGGTAACCC
GACGTTCAGCGGCAGATCGTCCATGG
doi:10.1371/journal.ppat.1002444.t001
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treated with 100 mM Na2CO3 for 1h on ice and centrifuged at
100,0006g in a TLA 100.3 rotor for 45 min at 4uC to separate the
pellet and supernatant, subsequently precipitated using TCA.
Equal amounts of input, pellet and supernatant were analyzed by
immunoblotting as above.
To determine the topology of proteins in the membrane, the
25,0006g membrane fractions were digested with 0.5 mg/ml
proteinase K in the absence or presence of 1% Triton X-100 for 1
hr at 37
oC. Reactions were stopped by adding 1 mM PMSF and
SDS sample buffer. Input and protease treated samples were
analyzed by immunoblotting.
Quantitative reverse transcriptase PCR
Targets were detected by qRT-PCR (Quantitative reverse-
transcription PCR) as described previously [22]. RNA was isolated
from TB40E-WT (Sample) or TB40E-UL133-UL138NULL (Con-
trol) infected cells and DNase treated using the NucleoSpin RNA
II kit (Machery-Nagel) and cDNA was generated using the
transcriptor first-strand cDNA synthesis kit (Roche) according to
the manufacturer’s instructions. qRT-PCR was performed with
the LightCycler 480 Probes Master (Roche) according to the
manufacturer’s instructions along with the Universal Probe
Library (Roche) probes and primers specific for UL133, UL135,
UL136 and UL138 [22]. IE1&2 genes were used as controls for
infection. The human b-actin gene was used as a reference and the
target levels were quantitated by a DDCT method using the
following equation [45].
DDCT~
Etarget
 DCTTarget(Control-Sample)
EReference ðÞ
DCTReference(Control-Sample)
Where, CT is the cycle threshold and E is the efficiency as
determined using the Light Cycler 480 software. In our analysis,
we considered a 2-fold change to be within the confidence interval
for equally abundant target.
Infectious centers assay
CD34
+ HPCs isolated from human cord blood were infected at
an MOI of 2 for 20 h in IMDM supplemented with 10% BIT9500
serum substitute (Stem Cell Technologies, Canada), 2 mM L-
Glutamine, 20 ng/ml low density lipoproteins and 50 mM2 -
mercaptoethanol. Following infection, pure populations of infected
CD34
+ HPCs (GFP-positive) were isolated by fluorescence-
activated cell sorting (FACSAria, BD Biosciences Immunocyto-
metry Systems, San Jose, CA) using a phycoerythrin-conjugated
antibody specific to CD34 (BD Biosciences) and cultured in
transwells above an irradiated (4000 rads,
137Cs gammacell-40
irradiator type B, Atomic Energy of Canada LTD, Ottawa,
Canada) M2-10B4 and S1/S1 stromal cell monolayer [39] for 10–
12 days. The frequency of infectious centers production during the
culture period was measured using a limiting dilution assay as
described previously [18]. Briefly, infected HPCs were serially
diluted 2-fold in LTBMC medium. An aliquot (0.05mL) of each
dilution was added to 12 wells (first dilution corresponds to 40,000
Table 2. Primers used for cloning into pCIG2 vector.
Primer name
a Sequence (59 to 39)
b
UL133-Fwd ccggaattcgctagcaccATGGGTTGCGACGTGCACGATCCTTCG
UL135-Fwd cgcggatccgctagcaccATGTCCGTACACCGGCCCTTCCCGACA
UL136-Fwd ccggaattcgctagcaccATGTCAGTCAAGGGCGTGGAGATGCCA
UL138-Fwd ggggGCTAGCACCATGGACGATCTGCCGCTGAACGTCG
C-Myc-Rev cgcggatccTCACAGATCCTCTTCTGAGATGAGTTTTTGTTC
UL1333xFLAG-Rev ggggGATATCTTACTTGTCGTCGTCGTCCTTGTAGTCGAATTCCTTGTC
GTCGTCGTCCTTGTAGTCTGCCCCTTTATCATCATCATCTTTATAATC
ACCGCCACCGCCCGTTCCGGTCTGATGC
UL135HA-Rev gggggatatcTCACGCGTAATCTGGAACATCGTATGGGTAACCGCCAC
CGCCGGTCATCTGCATTGACTCGGCGTCC
UL136myc-Rev gggggatatcTTACAGATCCTCTTCTGAGATGAGTTTTTGTTCACCGCC
ACCGCCCGTAGCGGGAGATACGGCGTTCTCC
UL138EE-Rev gggggatatcTCACTCCATGGGCATGTACTCACCGCCACCGCCCGTGTA
TTCTTGATGATAATGTACC
Bleo-Fwd ggggaccggtaccATGGCCAAGTTGACCAGTGCCGTTCCG
Bleo-Rev gggggcggccgcTCAGTCCTGCTCCTCGGCCACG
Neo-Fwd ggggaccggtaccATGGGATCGGCCATTGAACAAGATGGATTGC
Neo-Rev gggggcggccgcTCAGAAGAACTCGTCAAGAAGGCGATAGAAGG
Puro-Fwd ggggaccggtaccATGACCGAGTACAAGCCCACGGTGCG
Puro-Rev gggggcggccgcTCAGGCACCGGGCTTGCGGGTC
Hygro-Fwd ggggaccggtaccATGGATAGATCCGGAAAGCCTGAACTCACC
Hygro-Rev gggggcggccgcCTATTCCTTTGCCCTCGGACGAGTGC
aFwd: Forward; Rev: Reverse
bEnzyme sites are in lower case
doi:10.1371/journal.ppat.1002444.t002
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cells. MRC5 cells were monitored for GFP expression for a period
of 14 days. The frequency of infectious centers formed was
calculated based on the number of GFP
+ cells at each dilution
using software, Extreme limiting dilution analysis (ELDA, http://
bioinf.wehi.edu.au/software/elda) [46].
Engraftment and infection of humanized mice
NOD-scid IL2Rcc
null mice were maintained in a specific pathogen
free facility at Oregon Health and Science University in accordance
with Institutional Animal Care and Use Committee approved
procedures. Mice were sublethally irradiated with 250 cGy by
137Cs
g-irradiation and then engrafted with approximately 150,000
human CD34
+ stem cells (Catalog #CB008F-S, StemCell Tech-
nologies; Vancouver British Columbia, Canada) via retro-orbital
injection. At 4 weeks post inoculation of stem cells, the level of
engraftment (determined as the percentage of human CD45
+
present in the blood of total lymphocytes) was assessed by flow
cytometry as previously described [27]. At 5 weeks post engraft-
ment, the mice were infected by intraperitoneal injection of 1610
7
normal human dermal fibroblasts previously infected with HCMV
TB40E-WT or TB40E-UL133-UL138NULL. A third group of
engrafted mice were mock infected with uninfected human
fibroblasts. At 4 weeks post infection, a group of mice were treated
for 7 days with 100 ml of G-CSF (300 mg/ml; Amgen) via a
subcutaneous micro-osmotic pump (1007D; Alzet) and AMD3100
(5mg/kg) to mobilize their hematopoietic stem cells. As a direct
comparator for the effects of virus reactivation-dissemination
following mobilization an additional non-mobilized infected control
group was included for each virus (n=4/group). At 2 weeks post
mobilization, mice were euthanized and bone marrow and spleen
were harvested and snap frozen for subsequent analysis.
Quantitative PCR for viral genomes
Total DNA was extracted from 0.8 g of mouse spleen and bone
marrow via the DNAzol method (Life Technologies) and analyzed
by quantitative PCR (TaqMan) for the presence of HCMV
genomic DNA. For Q-PCR analysis, 1 mg of total DNA was
analyzed using primers and a probe recognizing HCMV US28
sequences (probe=TGA TCC CGC TCA GTG T; forward
primer=GAA CTC ATG CTC GGT GCT TTC; and reverse
primer=CTT TGT GGC GCG ACT GAG A). The probe
contains labeled with a 59-end FAM reporter molecule and a 39-
end quencher molecule (Applied Biosystems, Foster City, CA).
PCR reactions were prepared using TaqMan Universal PCR
Master Mix (Applied Biosystems) according to the manufacturer’s
instructions. To initiate the reaction the AmpliTaq Gold was
activated at 95uC for 10 minutes and then 40 cycles (15 s at 95uC
and 1 min at 60uC) were performed using a StepOnePlus
TaqMan PCR machine. Results were analyzed using ABI
StepOne software. The sensitivity of detection for this assay was
approximately 50 HCMV DNA genomic copies as determine by
using a plasmid containing the US28 amplicon to develop a
standard curve. Data were analyzed using the statistical program
GraphPad Prism 5.
Supporting Information
Figure S1 Virus replication of FIX recombinant viruses
at high MOI. Cells and media were collected 6 dpi following
MRC5 infection with FIX-UL133myc, FIX-UL135myc, FIX-
UL136myc and FIX-UL138myc recombinant viruses. Virus titers
were measured by TCID50. Bars represent the average of triplicate
experiments.
(EPS)
Table 3. Primary antibodies used for immunofluorescence and immunoblotting.
Antigen Antibody Type
a Source Dilution
Immunoflurescence
b,d,g Immunoblotting
c,d
UL133 Custom R Open Biosystems ND 2 mg/ml
UL135 Custom R Open Biosystems ND 2 mg/ml
UL138 Custom R Open Biosystems ND 2 mg/ml
IE1/2 3H4 M Gift
e ND 1:100
MHC-I, HLA-B/C HC10 M Gift
f ND 1:50
a-Tubulin DM 1A M Sigma ND 1:12,000
b-Actin ACTN05(C4) M abcam ND 1:1000
Golgi GM130 Clone 35 M BD Transduction 1:100 ND
Laboratories
Myc epitope 71D10 R Cell Signalling 1:200 1:1000
Myc epitope
g 9B11 M Cell Signalling 1:1000 1:1000
HA epitope
g HA7 M Sigma 1:100 ND
FLAG epitope
g M2 M Sigma 1:2000 1:1000
EE epitope
g R Bethyl 1:1000 ND
Laboratories, Inc
aR-Rabbit; M-Mouse monoclonal
bDilution in PBS supplemented with BSA and Tween 20
cDilution in TBS/5% milk supplemented with BSA and Tween 20
dND-Not done
eGenerous gift from Tom Shenk, Princeton University.
fGenerous gift from Lonnie Lybarger, University of Arizona.
gConjugated with Qdots 525nm (HA); 565nm (myc); 585nm (FLAG); 625nm (EE)
doi:10.1371/journal.ppat.1002444.t003
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pUL136 associate with microsomal membranes. (A) To
determine the membrane association of each viral protein in the
absence of virus infection, MRC5 cells were transduced with
lentiviruses expressing pUL133myc pUL135myc pUL136myc and
pUL138myc at an MOI of 1. Crude membrane fractions were
prepared at 48 hours post transduction by differential centrifuga-
tion as described in Figure 3A. To determine if the viral proteins
were integral membrane proteins, 25K microsomal membrane
fractions were treated with 100 mM Na2CO3 for 1 h on ice and
pelleted at 100,0006g for 1 h at 4
oC. Equal amounts of input,
pellet and supernatant were analyzed for specific proteins by
immunoblotting using a rabbit antibody specific to myc epitope
tag. (B) To determine the topology of proteins in the Golgi
membranes, 25K microsomal membrane fractions were treated
with 0.5 mg/ml proteinase K for 45 min at 37uC in the presence
or absence of 1% Triton X-100. Viral proteins were detected by
immunoblotting as described above. MHC I was used as a control
in panels A-B. The bands were quantified using Odyssey LiCor
software and the percent protein digestion in the absence or the
presence of Triton X-100 is indicated.
(EPS)
Figure S3 UL133-UL138NULL virus replication with high
MOI infection. To examine the replication kinetics of the
UL133-UL138NULL viruses relative to the wild type viruses at high
MOI, MRC5 cells were infected with (A) TB40E-UL133-
UL138NULL or (B) FIX-UL133-UL138NULL at 2 MOI and virus
titers measured by TCID50 at 6 dpi. Bars represent the averages of
triplicate experiments.
(EPS)
Figure S4 Localization of pUL133, pUL135, pUL136 and
pUL138 in the Golgi apparatus. MRC5 cells were mock-
infected or infected with TB40E-UL133-UL138NULL and then
transduced with lenti viruses encoding pUL133FLAG, pUL135HA,
pUL136myc, or pUL138EE. Proteins were co-localized by direct
immunofluorescence 48 hpi using monoclonal antibodies specific
to each epitope tag that had been directly conjugated to Quantum
dots of 525nm (HA); 565nm (Myc); 585nm (FLAG); 625nm (EE).
Cell nuclei are indicated by Qnuclear staining. Localization was
visualized using a Ziess 510 Meta Confocal microscope.
(TIF)
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